AlphaStocks
6.5
Consider Buy

Exelixis, Inc. (EXEL)

As of Sep 20, 2026, Exelixis, Inc. (EXEL) scores 6.5/10 on AlphaStocks' five-model composite, #29 of 168 Health Care stocks. At $58, EXEL trades 5% below its model fair value of $62.

Health Care / Biotechnology

S&P MidCap 400

$58.35

Middle of the pack. No strong signal either way.

Consider Buy

Score based on 4 of 5 models — moderate confidence

Data as of Sep 20, 2026

#29out of 168 in Health Care

Is EXELIXIS, INC. a Good Investment in 2026?

EXELIXIS, INC. (EXEL) scores 6.5 out of 10 on AlphaStocks' composite model, earning a Consider Buy rating. The Piotroski model rates EXELIXIS, INC. as Strong (7/9). However, the Graham model rates it Caution — Significantly above fair value. EXELIXIS, INC. currently trades 5% below its estimated fair value of $62. EXELIXIS, INC. ranks #29 out of 168 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E21.0ROE34.8Market Cap16B

Estimated Fair Value

$61.565% below

Trading near estimated fair value.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Strong

7/9

Buffett

Attractive

Business quality & competitive moat

Graham

Caution

Significantly above fair value

Lynch

Attractive

PEG 2.5 · Stalwart

Greenblatt

Limited Data

Earnings yield + return on capital

Frequently Asked Questions

Is EXELIXIS, INC. (EXEL) a good investment?
As of Sep 20, 2026, Exelixis, Inc. (EXEL) scores 6.5/10 on AlphaStocks' five-model composite, #29 of 168 Health Care stocks. At $58, EXEL trades 5% below its model fair value of $62. That is a middle-of-the-pack score with no strong signal either way.
What is EXELIXIS, INC.'s Piotroski F-Score?
EXELIXIS, INC.'s Piotroski F-Score status is Strong. The raw score is 7/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is EXEL overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $62, EXEL appears undervalued. The stock currently trades 5% below its estimated fair value. Trading near estimated fair value.
How does EXEL compare to other Health Care stocks?
EXELIXIS, INC. ranks #29 out of 168 stocks in the Health Care sector, placing it in the top 17% of its sector by composite score. This is a strong position relative to sector peers.
What do investment models say about EXEL?
AlphaStocks evaluates EXEL using five proven investment models. Piotroski: Strong; Buffett: Attractive; Graham: Caution; Lynch: Attractive. These models are combined into a single composite score of 6.5/10.

Similar Stocks

ABBVINCYHRMY

Compare EXEL with

ABBV vs EXELEXEL vs INCYEXEL vs HRMY

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer